Chandler Robinson - Dec 31, 2023 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Executive Officer, Director
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Dec 31, 2023
Transactions value $
-$3,673
Form type
4
Date filed
1/3/2024, 07:36 PM
Previous filing
Oct 3, 2023
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +24.5K +19.06% 153K Dec 31, 2023 Direct F1
transaction MNPR Common Stock Tax liability -$2.88K -8.47K -5.54% $0.34 144K Dec 31, 2023 Direct F2
transaction MNPR Common Stock Options Exercise +6.72K +4.66% 151K Jan 1, 2024 Direct F1
transaction MNPR Common Stock Tax liability -$792 -2.33K -1.54% $0.34 149K Jan 1, 2024 Direct F2
holding MNPR Common Stock 4.11M Dec 31, 2023 See Footnote F3
holding MNPR Common Stock 167K Dec 31, 2023 See Footnote F4
holding MNPR Common Stock 4.11M Dec 31, 2023 See Footnote F3
holding MNPR Common Stock 167K Dec 31, 2023 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -24.5K -9.66% $0.00 229K Dec 31, 2023 Common Stock 24.5K Direct F1, F5, F6, F7
transaction MNPR Restricted Stock Units Options Exercise $0 -6.72K -2.94% $0.00 222K Jan 1, 2024 Common Stock 6.72K Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3 This is based upon the 4,111,272.88 shares of Monopar common stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Dr. Robinson disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F4 This is based upon the 166,667 shares of Monopar common stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 166,667 shares. Dr. Robinson disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F5 On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6 On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F7 On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F8 On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.